• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Screening
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

ADA 2017: Hypoglycemia and the Role of Glycemic Variability

Slideshow
Conference|ADA

Glycemic variability fuels hypoglycemia but in one study from ADA 2017 is found to actually help predict hypoglycemic events.

Among studies presented at at the ADA 77th Scientific Sessions were evaluations of hypoglycemia incidence in large populations, the relation of glycemic variability to risk of hypoglycemia, and glycemic variability as an alternative method to predict hypoglycemia.Three stuides are summarized in the slides above; links to abstracts are provided in the captions.

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
Sotagliflozin Setback: Cautionary FDA AdComm Vote Reflects Continued Concern for Negative Risk/Benefit Ratio in T1D with CKD / image credit ©Tada Images/stock.adobe.com

Sotagliflozin Setback: Cautionary FDA AdComm Vote Reflects Continued Concern for Negative Risk/Benefit Ratio in T1D with CKD

Grace Halsey
November 1st 2024
Article

The FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 11 to 3 against recommending the SGLT1/SLGT2 inhibitor to treat adults with T1D and CKD.

Obesity & Type 2 Diabetes: An Expert Discussion

Obesity & Type 2 Diabetes: An Expert Discussion

Sydney Jennings
June 30th 2023
Podcast

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

GLP-1RAs Reduce the Risk of Early-Onset Colorectal Cancer in Adults with T2D / Image credit: American College of Gastroenterology (ACG)

GLP-1RAs Reduce the Risk of Early-Onset Colorectal Cancer in Adults with T2D

Sydney Jennings
October 31st 2024
Article

ACG 2024: New study results indicate GLP-1 RAs have a potentially protective role to play in combating EO-CRC, the incidence of which is notably rising worldwide.

Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

Sydney Jennings
July 22nd 2022
Podcast

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Hiddo Heerspink, PhD, PharmD.

Oral Semaglutide Shows 14% Reduction in MACE in Adults with T2D, ASCVD, and/or CKD: Topline Results from Phase 3 SOUL Trial / image credit heart and kidneys: ©krishnacreations/stock.adobe.com

Oral Semaglutide Shows 14% Reduction in MACE in Adults with T2D, ASCVD, and/or CKD: Topline Results from Phase 3 SOUL Trial

Grace Halsey
October 21st 2024
Article

Novo Nordisk plans to file for regulatory approval this year of an expanded label for oral semaglutide, with an indication for reduction of MACE in high-risk adults with T2D.

October Issue of Patient Care Online Supplement is Now Live

October Issue of Patient Care Online Supplement is Now Live

Sydney Jennings
October 14th 2024
Article

Find details on challenges primary care clinicians face in treating older adults with T2D and an expert discussion on navigating treatments to delay T1D.

© 2024 MJH Life Sciences

All rights reserved.